[A17-21] Nivolumab (classical Hodgkin lymphoma) - Addendum to Commission A16-76
Last updated 16.06.2017
Commission awarded on 11.05.2017 by the Federal Joint Committee (G-BA).
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-40||Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)||Commission completed|
|A16-76||Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|